Treatment of Relapsing Polychondritis in Myelodysplastic Syndrome or VEXAS Syndrome
This protocol addresses the management of relapsing polychondritis occurring in patients with myelodysplastic syndrome (MDS) or VEXAS syndrome — a setting that requires specialised, multidisciplinary care distinct from standard relapsing polychondritis management.
The initial treatment in this setting involves systemic corticosteroid therapy. The complete regimen — including sequencing, monitoring, and additional considerations specific to MDS or VEXAS — is detailed in the full protocol.
The treatment approach for patients with relapsing polychondritis associated with myelodysplastic syndrome as well as for VEXAS syndrome requires specialised management in collaboration with a team specialised in myelodysplastic syndrome.
Systemic corticosteroid therapy is used as the first line of treatment for the manifestations of relapsing polychondritis in this setting.